
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded troche containing methyltestosterone, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Methyltestosterone is a Schedule III controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing methyltestosterone are listed in capsule and tablet forms. No finished methyltestosterone product of any kind is listed in troche form.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Methyltestosterone is a synthetic androgen (male hormone) taken by mouth that a pharmacy may compound when a prescriber orders it.
Methyltestosterone is a man-made androgen related to testosterone, the main male sex hormone. A methyl group added at the 17-alpha position lets it be taken by mouth, because the liver breaks it down less than testosterone. Androgens develop and maintain male sex characteristics and affect muscle, fat distribution and red blood cell production. Manufactured products include Methitest tablets and generic methyltestosterone capsules (ANDA), labeled for replacement therapy in males with primary or hypogonadotropic hypogonadism, carefully selected males with clearly delayed puberty, and secondary use in certain women with advancing inoperable metastatic breast cancer. Esterified estrogens and methyltestosterone tablets are filed on DailyMed as unapproved drug other. A prescriber might order methyltestosterone compounded in a strength or form that is not manufactured, or without a particular dye or excipient. Compounded preparations are not FDA-approved and require a prescription.
Methyltestosterone labels carry no boxed warning. Do not use it if you are a man with breast cancer or known or suspected prostate cancer, or if you are or may become pregnant, because androgens can masculinize a female fetus. The label warns of liver problems: cholestatic hepatitis and jaundice can occur, and long-term high doses have been linked to blood-filled liver cysts (peliosis hepatis) and liver tumors. Other warnings include blood clots in the legs or lungs, higher blood pressure, fluid retention in people with heart, kidney or liver disease, and early bone maturation that can reduce adult height in children. Women should report a deeper voice, facial hair, acne or period changes; stopping early helps prevent permanent changes. It can lower the dose needed of oral blood thinners and insulin. The label says to choose between nursing and the drug. Talk to your prescriber or pharmacist about side effects.
Methyltestosterone is a 17-alpha-alkylated androgen; per the ANI capsule label it is less extensively metabolized by the liver than testosterone and has a longer half-life, making it more suitable for oral use. LiverTox notes that 17-alpha alkylation inhibits hepatic deactivation and that this class is linked to bland cholestasis, peliosis hepatis, hepatic adenoma and hepatocellular carcinoma, with cholestasis not described with unmodified testosterone. Labeled indications (Methitest tablets and methyltestosterone capsules, ANDA): primary and hypogonadotropic hypogonadism, delayed puberty in selected males, and secondary therapy in inoperable metastatic breast cancer in women 1 to 5 years postmenopausal. Safety and efficacy in age-related hypogonadism are not established. Confirm hypogonadism with morning serum testosterone measured on at least two separate days before starting. Monitor liver function periodically, hemoglobin and hematocrit for polycythemia, blood pressure, serum and urine calcium in breast cancer, bone age every 6 months in prepubertal males, and anticoagulation when starting or stopping. Androgens can lower thyroxine-binding globulin and total T4. Dosing is per prescriber. Methyltestosterone is a Schedule III controlled substance. Under DEA rules, electronic prescribing of controlled substances is voluntary, though more stringent state requirements supersede DEA's. Separately, CMS requires that at least 70% of each prescriber's Part D Schedule II to V prescriptions be sent electronically, with exceptions, and states may set their own requirements; Pennsylvania, for example, requires e-prescribing of Schedule II to V drugs.
Wash and dry your hands. Place the troche between your cheek and gum or under your tongue, as your label directs, and let it dissolve. Do not chew or swallow it whole unless told to. Dissolving can take up to 30 minutes. Follow your label about eating or drinking around the dose.
Troches are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in the closed container in a cool, dry place at room temperature, away from heat so they do not soften, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve